SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending after reporting positive Phase 1 clinical trial data for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile, particularly in treatment-resistant patients. The news has ignited significant community discussion around a potential short squeeze and sustained bullish momentum, with many anticipating future partnerships or a buyout. This early success in a large therapeutic market is generating considerable interest in the stock's long-term potential.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility due to renewed global trade tensions, specifically concerning former President Trump's comments on Greenland and potential tariffs on European allies. The community is sharply divided, with bears anticipating a deeper market correction driven by geopolitical concerns and bond market stability, while bulls are aggressively buying dips, confident in a swift rebound and a potential policy reversal. This dynamic creates significant swings as participants debate the market's underlying strength amidst uncertainty.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to significant market instability sparked by high-profile geopolitical rhetoric and broader financial concerns, including stress in Japan's bond market. The crypto community is intensely debating Bitcoin's status as a reliable hedge asset, noting substantial liquidations even as prominent institutions continue making large acquisitions. This dynamic creates a highly volatile environment and fuels ongoing discussion about its near-term trajectory.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its earnings report, with community sentiment sharply divided on whether subscriber growth and ad-tier performance will spark a rally or a significant drop. The recent all-cash offer for Warner Bros. Discovery assets is a key discussion point, seen by some as a strategic play to secure the deal and by others as a potentially costly move impacting future debt. Traders are also noting the stock's oversold conditions, with some positioning for a rebound despite broader market uncertainties.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is a trending topic amidst a prolonged downtrend and consistent selling pressure, defying recent positive reports of strong iPhone sales and market share gains, particularly in China. The community remains sharply divided, with many expressing frustration over its 'oversold' status and speculating on market manipulation, while others view the pullback as a significant buying opportunity ahead of its upcoming earnings report and potential clarifications on its AI strategy, including its partnership with Google Gemini.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of Zydus Lifesciences exploring a controlling stake or key asset acquisition, alongside strong preliminary revenue figures and a significant patent extension for IBSRELA and XPHOZAH until 2041. The community is buzzing about the game-changing patent extension, accelerating IBSRELA's path to $1 billion in annual revenue by 2029, and speculating on a potential buyout or bidding war, despite some historical skepticism around sustained gains. Analysts have responded with multiple price target upgrades, highlighting the company's strengthened long-term valuation and potential for sustained growth with two approved drugs.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following multiple analyst upgrades, renewed investor optimism from CES, and significant news of winning a U.S. SHIELD defense contract for advanced chip manufacturing. The community is actively debating the stock's ability to break through key resistance levels, with many believing the company is undervalued amidst the ongoing AI race and its strategic position in domestic chip production, despite some Wall Street caution ahead of upcoming earnings.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oculis (NASDAQ:OCS) Reaches New 1-Year High - Here's Why

Oculis (NASDAQ:OCS) Hits New 1-Year High - Here's What Happened...

Oculis (NASDAQ:OCS) Shares Gap Up - What's Next?

Oculis (NASDAQ:OCS) Shares Gap Up - What's Next...

Oculis (NASDAQ:OCS) Shares Gap Up - Should You Buy?

Oculis (NASDAQ:OCS) Shares Gap Up - Here's What Happened...

Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 101,167 shares, a growth of 105.6% from...

Oculis (NASDAQ:OCS) Shares Down 4.3% - Time to Sell?

Oculis (NASDAQ:OCS) Trading Down 4.3% - Should You Sell...

Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade

Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade...

Oculis (NASDAQ:OCS) Price Target Raised to $40.00 at Stifel Nicolaus

Stifel Nicolaus boosted their target price on shares of Oculis from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday...

Oculis (NASDAQ:OCS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on Oculis in a research report on Friday. They issued an "overweight" rating and a $38.00 target price on the stock...

Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of "Moderate Buy" from Analysts

Oculis Holding AG (NASDAQ:OCS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. One analyst has...

Oculis (NASDAQ:OCS) Trading Down 6% - Should You Sell?

Oculis (NASDAQ:OCS) Trading Down 6% - Time to Sell...

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

OCS
Oculis Holding AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCS News

OCSOculis Holding AG